bioRxiv · 10.1101/2023.06.29.547129
p53-Bad* in a Hepatocellular Carcinoma Mouse Model
Abstract
Recent advances in liver cancer treatments have not changed the fact that the majority of patients will not survive the disease. In order to advance future liver cancer treatments, this work presents an exploration of various iterations of the liver cancer specific AFP promoter as well as the gene construct p53-Bad*. p53-Bad* is a mitochondrially targeted re-engineered p53 therapy that has shown previous success in a zebrafish HCC model. Both the most promising AFP promoter and p53-Bad* were packaged in an adenoviral delivery system and tested in vitro in liver cancer cell lines. Finally, mixed results for adenoviral p53-Bad* in vivo are presented, and this work suggests future modifications to study parameters in order to further explore the potential of p53-Bad* as a potential liver cancer therapeutic.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Bowman, K. E. R., Lu, P., Lim, C. S.. 2023-06-29. p53-Bad* in a Hepatocellular Carcinoma Mouse Model. https://doi.org/10.1101/2023.06.29.547129
Cite the original work for its findings. Save a collection to share your selection of sources.